Cargando…
Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey
In post-stroke patients, a decreased adherence to antiplatelet drugs is a major challenge in the prevention of recurrent stroke. Previously, we reported an antiplatelet vaccine against S100A9 in mice, but the use of Freund’s adjuvant and the difference in amino acid sequences in epitopes between mic...
Autores principales: | Shimamura, Munehisa, Kaikita, Koichi, Nakagami, Hironori, Kawano, Tomohiro, Ju, Nan, Hayashi, Hiroki, Nakamaru, Ryo, Yoshida, Shota, Sasaki, Tsutomu, Mochizuki, Hideki, Tsujita, Kenichi, Morishita, Ryuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169762/ https://www.ncbi.nlm.nih.gov/pubmed/34075153 http://dx.doi.org/10.1038/s41598-021-91153-y |
Ejemplares similares
-
Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice
por: Shimamura, Munehisa, et al.
Publicado: (2018) -
A novel angiotensin II peptide vaccine without an adjuvant in mice
por: Nakamaru, Ryo, et al.
Publicado: (2021) -
Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice
por: Kawano, Tomohiro, et al.
Publicado: (2019) -
Therapeutic vaccine for chronic diseases after the COVID-19 Era
por: Nakagami, Hironori, et al.
Publicado: (2021) -
Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke
por: Shimamura, Munehisa, et al.
Publicado: (2018)